Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 177,704 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $11.54, for a total transaction of $2,050,704.16. Following the transaction, the chief operating officer now owns 740,976 shares in the company, valued at $8,550,863.04. This represents a 19.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $11.83 on Wednesday. The firm has a market cap of $8.61 billion, a price-to-earnings ratio of 2.09 and a beta of 1.25. The stock’s fifty day simple moving average is $11.91 and its 200 day simple moving average is $11.55. Roivant Sciences Ltd. has a one year low of $9.69 and a one year high of $13.06.

Wall Street Analyst Weigh In

ROIV has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. Bank of America upped their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. Clearbridge Investments LLC increased its holdings in shares of Roivant Sciences by 51.3% during the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after buying an additional 630,712 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Roivant Sciences by 40.1% in the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after purchasing an additional 185,226 shares in the last quarter. Exchange Traded Concepts LLC acquired a new stake in shares of Roivant Sciences in the third quarter valued at $2,267,000. TOMS Capital Investment Management LP acquired a new position in Roivant Sciences during the 3rd quarter worth about $46,333,000. Finally, Loomis Sayles & Co. L P grew its holdings in Roivant Sciences by 13.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock worth $45,147,000 after acquiring an additional 458,601 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.